Evaluation of Endothelial Glycocalyx in the Surgical Resuscitation of Major Burn Patients

Launched by HOSPITAL UNIVERSITARI VALL D'HEBRON RESEARCH INSTITUTE · Oct 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a condition called Endotheliopathy of Trauma (EoT) affects severely burned patients, particularly during and after a specific type of surgery known as burn debridement. EoT can impact the tiny blood vessels and the protective layer around them, which may be important for recovery. The researchers want to find out if patients have EoT before their surgery and whether the surgery makes this condition worse. To do this, they will measure a substance called syndecan 1 (sdc 1) in the patients' blood before and after the surgery.

To be eligible for this study, participants must be adults over 18 years old with severe burns covering at least 20% of their body. They should be scheduled for surgery that involves removing damaged tissue from at least 20% of their burned areas. During the trial, patients can expect to have their blood tested for sdc 1 levels and undergo an analysis to see how various factors might affect their recovery. This research aims to provide valuable information that could help improve care for severely burned patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years old with burned TBSA greater than or equal to 20%.
• • Patients who will undergo debridement of at least 20% of the burned TBSA (including the debrided area and the donor site).
• Exclusion Criteria:
• • Under 18 years old.
• • Pregnant women.
• • Patient refusal.
• • Polytraumatized patients.
• • Electrical or chemical burns.
• • Patients with any of the following pre-burn conditions: complicated heart disease\*, renal disease on hemodialysis/hemofiltration or with Glomerular Filtration Rate (GFR) \< 30 ml/min/1.73m², and liver cirrhosis (Child A, B, and C).
• • (\* Definition of complicated heart disease: decompensated heart failure (NYHA class IV), Left Ventricular Ejection Fractio \< 40%, or severe valvular disease).
• • Patients with a history of chronic inflammatory diseases (autoimmune disease).
• • Patients on chronic treatment with corticosteroids or immunosuppressants.
• • Patients requiring reintervention for debridement surgery who have already been included in the study during their first surgery.